ED drugs slapped with new warning

Here's a trade-off that could have been dreamed up by a Puritan: Treat your ED, go deaf. The FDA is adding new warnings of sudden hearing loss to three of the popular ED drugs--you know their names. The agency doesn't have proof that the drugs caused sudden deafness but decided to add the warning after digging up 29 reports of the problem since 1996. The scary part, agency officials said, was that these patients lost their hearing--in one ear only--within two days of starting on the meds, sometimes within hours. In a third of the cases, the loss was temporary.

- read the FDA warning
- check out the report from the Associated Press

Related Articles:
Gene therapy approach may work against ED. Report
Safety concerns force delay for Phase III ED trial. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.